Idysbetalipoproteinemia eqhelekileyo yosapho

Idysbetalipoproteinemia eqhelekileyo yosapho kukuphazamiseka okudluliswa kwiintsapho. Yenza i-cholesterol eninzi kunye ne-triglycerides egazini.

Isiphene semfuza sibangela le meko. Isiphene siphumela ekwakhiweni kwamasuntswana amakhulu eepoprotein aqukethe zombini i-cholesterol kunye nohlobo lwamafutha abizwa ngokuba yi-triglycerides. Esi sifo sinxulunyaniswa neziphene kwimfuza yeapolipoprotein E.

I-Hypothyroidism, ukutyeba kakhulu, okanye isifo seswekile zinokuyenza mandundu imeko. Imiba yomngcipheko wedysbetalipoproteinemia yosapho ibandakanya imbali yosapho yesifo okanye isifo semithambo.

Iimpawu azinakubonwa de kube yiminyaka engama-20 okanye ngaphezulu.

Iidipozithi ezimthubi zezinto ezinamanqatha kulusu olubizwa ngokuba yi-xanthomas zinokubonakala kwiinkophe, ezintendeni zezandla, ematheni ezinyawo, okanye kwimisipha yamadolo kunye neengqiniba.

Ezinye iimpawu zingabandakanya:

• Intlungu yesifuba (i-angina) okanye ezinye iimpawu zesifo se-coronary disease zingabakho mncinci
• Ukuxinana kwithole elinye okanye omabini xa uhamba
• Izilonda ezinzwaneni ezingaphilisiyo
• Iimpawu ezinje ngequbuliso ezinje ngengxaki yokuthetha, ukujinga kwelinye icala lobuso, ubuthathaka bengalo okanye umlenze, kunye nelahleko yokulinganisa

Uvavanyo olunokwenziwa ukufumanisa le meko lubandakanya:

• Uvavanyo lwe-genetic yeapolipoprotein E (apoE)
• Uvavanyo lwegazi lepaneli yeLipid
• Inqanaba leTriglyceride
• Uvavanyo lwe-lipoprotein ephantsi kakhulu (VLDL)

Injongo yonyango kukulawula iimeko ezinje ngokutyeba, i-hypothyroidism, kunye neswekile.

Ukwenza utshintsho kwindlela otya ngayo ukunciphisa iikhalori, amafutha, kunye necholesterol kunokunceda ukuthoba i-cholesterol egazini.

Ukuba amanqanaba e-cholesterol kunye ne-triglyceride asephezulu emva kokuba wenze utshintsho kwindlela otya ngayo, umboneleli wakho wezempilo unokuthatha amayeza ngokunjalo. Amayeza okunciphisa i-triglyceride yegazi kunye namanqanaba e-cholesterol aquka:

• Iileyile ezikhupha intlaka yeasidi.
• Iifibrate (gemfibrozil, fenofibrate).
• Nicotinic acid.
• Iingxelo.
• I-PCSK9 inhibitors, ezinje nge-alirocumab (Ixabiso elixabisekileyo) kunye ne-evolocumab (Repatha). Oku kubonisa udidi olutsha lweziyobisi ukunyanga i-cholesterol.

Abantu abanale meko banomngcipheko okonyuke kakhulu wesifo se-coronary disease kunye nesifo se-vascular peripheral.

Ngonyango, uninzi lwabantu luyakwazi ukunciphisa kakhulu amanqanaba e-cholesterol kunye ne-triglycerides.

Iingxaki zinokubandakanya:

• Ukuhlaselwa yintliziyo
• Ukubetha
• Isifo se-vascular peripheral
• Ukucaciswa okungaphakathi
• I-Gangrene yeziphelo ezisezantsi

Fowunela umnikezeli wakho ukuba ufumene ukuba unale ngxaki kwaye:

• Iimpawu ezintsha ziyavela.
• Iimpawu aziphuculanga kunyango.
• Iimpawu ziba nzima.

Ukuvavanya amalungu osapho abantu abanale meko kunokukhokelela ekufumanekeni kwangethuba kunye nonyango.

Ukunyangwa kwangethuba kunye nokuthintela ezinye izinto ezinje ngokutshaya kunokunceda ekuthinteleni ukuhlaselwa yintliziyo kwangethuba, ukubetha, nokuthintela imithambo yegazi.

Uhlobo lwe-III hyperlipoproteinemia; I-apolipoprotein engasebenziyo okanye enesiphene E

• Imithambo yegazi

UGenest J, uLibby P.Lipoprotein ukuphazamiseka kunye nesifo sentliziyo. Ku: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, ii-eds. Isifo sentliziyo seBraunwald: Incwadi yesifundo seMpilo yeNtliziyo. Ngomhla we-11. IPhiladelphia, PA: Elsevier; I-2019: isahluko 48.

URobinson JG. Ukuphazamiseka kwemetabolism yelipid. Ku: IGoldman L, iSchafer AI, ii-eds. Amayeza eGoldman-Cecil. Ngomhla wama-26. IPhiladelphia, PA: Elsevier; 2020: isahl. 195.